Study guide
9.5 Surfactant Biology, Products & Dosing
NBRC RRT-NPS Neonatal/Pediatric Specialist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neonatal and Pediatric Patient Assessment
1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage
2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring
2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics
3 Chapter 3: Airway Management & Secretion Clearance
3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning
4 Chapter 4: Pharmacology & Medical Gas Therapy
4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation
5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders
5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration
6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety
6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care
7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation
7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk
8 Chapter 8: High-Frequency Ventilation & Advanced Modes
8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure
9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy
9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response
10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness
10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains
11 Chapter 11: Congenital Heart Disease & Hemodynamic Management
11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS
12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care
12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation
9.5 Surfactant Biology, Products & Dosing
Key Takeaways Explain This Topic AI
Surfactant is mostly lipid with SP-B/SP-C supporting film function and SP-A/SP-D supporting host defense. Complete SP-B deficiency often causes severe, treatment-refractory neonatal disease, while genotype and phenotype determine course and specialist options.
Surfactant lowers surface tension as lung volume falls, improving alveolar stability and FRC and reducing—but not necessarily eliminating—atelectasis and intrapulmonary shunt in neonatal RDS.
Commercial preparations differ by source, concentration, and dosing: Poractant alfa (Curosurf, porcine, 80 mg/mL) is dosed at 200 mg/kg (2.5 mL/kg) initially, then 100 mg/kg (1.25 mL/kg) Q12h; Beractant (Survanta, bovine, 25 mg/mL) is dosed at 100 mg/kg (4.0 mL/kg) Q6h; Calfactant (Infasurf, calf lung, 35 mg/mL) is dosed at 105 mg/kg (3.0 mL/kg) Q12h.
Last updated: September 2026
9.5 Surfactant Biology, Products & Dosing
Neonatal Respiratory Distress Syndrome (RDS), historically known as hyaline membrane disease, is the primary cause of respiratory failure in premature neonates. RDS is caused by developmental deficiency in endogenous pulmonary surfactant. The introduction of exogenous surfactant replacement therapy revolutionized neonatal intensive care, drastically decreasing neonatal mortality and pneumothorax rates. The Neonatal/Pediatric Specialist must master surfactant biochemistry, commercial preparations, advanced delivery methods, and the rapid mechanical ventilator adjustments required immediately following administration.
Biophysical Composition & Physiology of Natural Surfactant
Endogenous pulmonary surfactant is synthesized, packaged, and secreted by Type II alveolar pneumocytes . It is stored intracellularly in lamellar bodies and exocytosed into the alveolar liquid hypophase lining the alveolar epithelium. PULMONARY SURFACTANT BIOCHEMICAL PROFILE
- ┌────────────────────────────────────────────────────────────────────────┐
- │ 90% LIPIDS (Phospholipids) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ • Dipalmitoylphosphatidylcholine (DPPC / Lecithin) ~50% │
- │ Amphipathic molecule; tight hydrophobic intermolecular packing │
- │ Lowers surface tension to near 0 dynes/cm at low lung volumes │
- │ • Phosphatidylglycerol (PG) ~8–10% │
- │ Marker of fetal lung maturity; promotes spreading of DPPC monolayer │
- │ • Phosphatidylinositol (PI), Phosphatidylethanolamine, Neutral Lipids │
- └────────────────────────────────────────────────────────────────────────┘
- │
- ▼
- ┌────────────────────────────────────────────────────────────────────────┐
- │ 10% SURFACTANT PROTEINS (SP) │
- ├────────────────────────────────────────────────────────────────────────┤
- │ HYDROPHILIC COLLECTINS (Host Defense) │
- │ • SP-A: Opsonizes bacteria, viruses, and fungi; pathogen clearance │
- │ • SP-D: Modulates alveolar inflammation; pathogen clearance │
- │ │
- │ HYDROPHOBIC APOPROTEINS (Surface Tension & Film Kinetics) │
- │ • SP-B: Essential for life; accelerates DPPC monolayer film formation │
- │ and stability; complete deficiency often causes severe disease │
- │ • SP-C: Enhances lipid insertion; prevents film collapse during breath │
- └────────────────────────────────────────────────────────────────────────┘
- 1. Surfactant Proteins & Congenital Deficiency Syndromes
SP-A & SP-D (Hydrophilic): Members of the collectin protein family. They possess collagen-like domains and carbohydrate recognition domains that bind microbial pathogens, facilitating macrophage phagocytosis and immune clearance. They play minimal direct roles in lowering surface tension.
SP-B & SP-C (Hydrophobic): Small, highly lipophilic peptides that integrate directly into the phospholipid bilayer. They accelerate the adsorption of DPPC from lamellar myelin aggregates into a continuous monolayer at the air-liquid interface.
Congenital SP-B Deficiency:
Biallelic pathogenic variants in SFTPB can produce inherited surfactant dysfunction.
Complete deficiency often presents in a term infant with severe diffuse disease that resembles RDS and responds poorly or only transiently to exogenous surfactant.
Presentation and course vary by variant; genetic testing and specialist evaluation are central, and lung transplantation may be considered for otherwise progressive severe disease.
2. Physical Mechanics: The Law of Laplace
Alveolar mechanics can be modeled using the Law of Laplace for a spherical liquid-air interface: P = 2 ⋅ γ r P = \frac{2 \cdot \gamma}{r} P = r 2 ⋅ γ
Where:
P = P = P = collapsing (inward distending) pressure
γ = \gamma = γ = surface tension at the liquid-air interface
r = r = r = alveolar radius
The Surfactant-Deficient Lung: Without surfactant, surface tension ( γ \gamma γ ) remains constant at approximately 70 dynes/cm 70\text{ dynes/cm} 70 dynes/cm (the surface tension of water). According to Laplace's equation, as alveolar radius ( r r r ) decreases, collapsing pressure ( P P P ) increases exponentially. Consequently, smaller alveoli generate high collapsing pressures and empty their gas into adjacent larger alveoli, culminating in widespread microatelectasis, loss of Functional Residual Capacity (FRC), intrapulmonary right-to-left shunting, and severe refractory hypoxemia.
The Surfactant-Sufficient Lung: Surfactant forms an amphipathic monolayer. During expiration, as alveolar surface area shrinks, DPPC molecules are tightly compressed together, driving surface tension ( γ \gamma γ ) down to < 2 to 5 dynes/cm < 2\text{ to }5\text{ dynes/cm} < 2 to 5 dynes/cm (near zero). By reducing γ \gamma γ in direct proportion to radius ( r r r ), the collapsing pressure ( P P P ) remains low and equal across alveoli of all sizes. Alveoli remain patent at end-expiration, preserving FRC and lung compliance.
Commercial Surfactant Preparations & Dosing
Natural exogenous surfactants derived from animal lungs are standard of care; synthetic protein-free surfactants were discontinued due to inferior efficacy.
Table 9.3.1: Comparison of Commercial Exogenous Surfactant Preparations
Generic Name Brand Name Animal Source Concentration Initial Dose Repeat Dosing & Schedule Maximum Total Doses
Poractant alfa Curosurf Porcine (pig) minced lung extract 80 mg/mL 80\text{ mg/mL} 80 mg/mL 200 mg/kg 200\text{ mg/kg} 200 mg/kg ; ( 2.5 mL/kg 2.5\text{ mL/kg} 2.5 mL/kg ) 100 mg/kg 100\text{ mg/kg} 100 mg/kg ( 1.25 mL/kg 1.25\text{ mL/kg} 1.25 mL/kg ); every 12 hours Up to 3 doses (initial + 2 repeat doses)
Beractant Survanta Bovine (cow) minced lung extract + additives 25 mg/mL 25\text{ mg/mL} 25 mg/mL 100 mg/kg 100\text{ mg/kg} 100 mg/kg ; ( 4.0 mL/kg 4.0\text{ mL/kg} 4.0 mL/kg ) 100 mg/kg 100\text{ mg/kg} 100 mg/kg ( 4.0 mL/kg 4.0\text{ mL/kg} 4.0 mL/kg ); every 6 hours Up to 4 doses within first 48 hours
Calfactant Infasurf Calf lung lavage extract 35 mg/mL 35\text{ mg/mL} 35 mg/mL 105 mg/kg 105\text{ mg/kg} 105 mg/kg ; ( 3.0 mL/kg 3.0\text{ mL/kg} 3.0 mL/kg ) 105 mg/kg 105\text{ mg/kg} 105 mg/kg ( 3.0 mL/kg 3.0\text{ mL/kg} 3.0 mL/kg ); every 12 hours Up to 3 doses
Clinical Pharmacology Nuances
Poractant Alfa (Curosurf) Advantage: Formulated at a high phospholipid concentration ( 80 mg/mL 80\text{ mg/mL} 80 mg/mL ). This allows delivery of an initial dose of 200 mg/kg 200\text{ mg/kg} 200 mg/kg in a small liquid volume of only 2.5 mL/kg 2.5\text{ mL/kg} 2.5 mL/kg . Clinical trials demonstrate that an initial 200 mg/kg 200\text{ mg/kg} 200 mg/kg dose of Curosurf results in faster weaning of F i O 2 FiO_2 F i O 2 and lower neonatal mortality compared to 100 mg/kg 100\text{ mg/kg} 100 mg/kg doses of Survanta or Infasurf. Furthermore, the lower fluid volume significantly decreases the incidence of transient airway obstruction during instillation.
Preparation & Handling:
Must be stored refrigerated at 2 ∘ C to 8 ∘ C 2^\circ\text{C to }8^\circ\text{C} 2 ∘ C to 8 ∘ C and protected from light.
Before administration, warm slowly to room temperature by allowing the vial to stand at room temperature for at least 20 minutes , or warm in the palm of the hand for at least 8 minutes .
NEVER use artificial warming devices, microwaves, or hot water baths!
Inspect the suspension: Curosurf is creamy white to light brown; Survanta is off-white to brown; Infasurf is off-white. Gently invert or swirl the vial to suspend; NEVER shake vigorously , as excessive agitation causes foaming and denatures the hydrophobic apoproteins.